View Main Condition: Mucopolysaccharidoses (MPS)
Mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, is a progressive condition that affects most tissues and organs. The severity of MPS VII varies widely among affected individuals.
Mutations in the GUSB gene cause MPS VII. This gene provides instructions for producing the beta-glucuronidase (β-glucuronidase) enzyme, which is involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs). GAGs were originally called mucopolysaccharides, which is where this condition gets its name. Mutations in the GUSB gene reduce or completely eliminate the function of β-glucuronidase. The shortage (deficiency) of β-glucuronidase leads to the accumulation of GAGs within cells, specifically inside the lysosomes. Lysosomes are compartments in the cell that digest and recycle different types of molecules. Conditions such as MPS VII that cause molecules to build up inside the lysosomes are called lysosomal storage disorders. The accumulation of GAGs increases the size of the lysosomes, which is why many tissues and organs are enlarged in this disorder. Researchers believe that the GAGs may also interfere with the functions of other proteins inside the lysosomes and disrupt many normal functions of cells.
The exact incidence of MPS VII is unknown, although it is estimated to occur in 1 in 250,000 newborns. It is one of the rarest types of mucopolysaccharidosis.
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Chester Whitley is a Pediatrics specialist and a Medical Genetics expert in Minneapolis, Minnesota. Whitley has been practicing medicine for over 43 years and is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome). He is also highly rated in 34 other conditions, according to our data. His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), Gangliosidosis, and GM1 Gangliosidosis. He is licensed to treat patients in Minnesota. Whitley is currently accepting new patients.
William Sly is a General Practice expert in Tampere, Finland. Sly is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome). He is also highly rated in 5 other conditions, according to our data. His top areas of expertise are Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome), and Mucopolysaccharidosis Type 4A (MPS IVA, Morquio Syndrome Type A).
Raymond Wang is a Pediatrics specialist and a Medical Genetics expert in Orange, California. Wang has been practicing medicine for over 22 years and is rated as an Elite expert by MediFind in the treatment of Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome). He is also highly rated in 22 other conditions, according to our data. His top areas of expertise are Mucopolysaccharidoses (MPS), Mucopolysaccharidosis Type 7 (MPS VII, Sly Syndrome), Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome), and Pompe Disease. He is licensed to treat patients in California.
Summary: The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.
Summary: This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP).
Published Date: August 01, 2010Published By: National Institutes of Health